Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 20 min ago
Peer-reviewedCC BYPharmaceutics

GLP-1 Receptor Agonists in Chronic Inflammatory Skin Diseases: Immunometabolic Mechanisms and Translational Perspectives

  • Klara Andrzejczak1
  • Emilia Kucharczyk1
  • Matylda Korgiel1
  • Justyna Drozdowska1
  • Joanna Maj2
  • Małgorzata Ponikowska2
  1. 1Faculty of Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland
  2. 2University Centre of General Dermatology and Oncodermatology, Wroclaw Medical University, 50-556 Wroclaw, Poland
Open at sourceDOICite

Abstract

Chronic inflammatory skin diseases, including psoriasis, hidradenitis suppurativa (HS), and atopic dermatitis (AD), are increasingly recognized as systemic disorders associated with chronic immune dysregulation. Growing evidence supports their links with metabolic disorders, reflected in heightened interest in therapeutic strategies targeting the immunometabolic axis. This review summarizes current knowledge on the role of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in the regulation of immune and metabolic processes in chronic inflammatory skin diseases, with particular emphasis on molecular mechanisms and available experimental and clinical data. GLP-1RAs, widely used in the treatment of type 2 diabetes and obesity, may also exhibit anti-inflammatory and immunomodulatory properties beyond their classical metabolic effects. GLP-1 signalling can influence keratinocyte function, immune cell activity, and wound healing. Furthermore, it modulates multiple intracellular signalling pathways, including cAMP/PKA, AMPK, PI3K/Akt, and NF-κB, as well as immune axes such as IL-23/Th17/IL-17 and inflammasome-related signalling. Available evidence suggests that GLP-1RAs may reduce inflammation and disease activity in selected inflammatory dermatoses. However, current evidence remains limited and is based primarily on experimental studies, case reports, and small-scale observational studies. Further well-designed clinical trials are needed to better define the therapeutic potential of GLP-1RAs and their role in dermatological practice.

Related

  1. MSC-derived extracellular vesicles for spinal cord injury: inflammatory microenvironment modulation, stage-dependent repair mechanisms, and translational challenges
    Hang Yu, Yifan Liu, Shulong Yin +7
    Frontiers in cellular neurosciencePeer-reviewedCC BYFull textNeuroscienceEurope PMC
  2. Metabolic Dysregulation and Metabolite-Targeted Interventions in Autism Spectrum Disorder: Mechanisms and Translational Perspectives
    Yu Fang, Zechen Dou, Yanan Liu +5
    MetabolitesPeer-reviewedCC BY 4.0Full textNeuroscienceCrossrefEurope PMC
  3. Bee-Derived Products in Neurodegenerative Diseases: Bioactive Constituents, Redox-Modulating Mechanisms, Evidence, and Translational Perspectives
    Jakub Garbarek, Oskar Hys, Alina Woźniak +2
    Molecules (Basel, Switzerland)Peer-reviewedCC BYFull textZoology & animal behaviourEurope PMCCrossref
  4. Epithelial inflammatory memory in ulcerative colitis: molecular mechanisms and translational implications
    Ge Jin, Wenjing Li, Fei Chen +2
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0ImmunologyFrontiersCrossref
  5. Mitochondrial quality control and intestinal barrier dysfunction in inflammatory bowel disease: knowledge mapping and translational perspectives on traditional Chinese medicine-derived bioactive compounds
    Yuanting Mao, Guopei Zhou, Xiaojian Li +2
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0ImmunologyFrontiersCrossref

Cite

BibTeXRIS
BibTeX
@article{andrzejczak2026glp1,
  title = {{GLP-1 Receptor Agonists in Chronic Inflammatory Skin Diseases: Immunometabolic Mechanisms and Translational Perspectives}},
  author = {Klara Andrzejczak and Emilia Kucharczyk and Matylda Korgiel and Justyna Drozdowska and Joanna Maj and Małgorzata Ponikowska},
  journal = {Pharmaceutics},
  year = {2026},
  month = may,
  doi = {10.3390/pharmaceutics18050605},
  url = {https://doi.org/10.3390/pharmaceutics18050605},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - GLP-1 Receptor Agonists in Chronic Inflammatory Skin Diseases: Immunometabolic Mechanisms and Translational Perspectives
AU  - Klara Andrzejczak
AU  - Emilia Kucharczyk
AU  - Matylda Korgiel
AU  - Justyna Drozdowska
AU  - Joanna Maj
AU  - Małgorzata Ponikowska
PY  - 2026
DA  - 2026/05/15
JO  - Pharmaceutics
DO  - 10.3390/pharmaceutics18050605
UR  - https://doi.org/10.3390/pharmaceutics18050605
AB  - Chronic inflammatory skin diseases, including psoriasis, hidradenitis suppurativa (HS), and atopic dermatitis (AD), are increasingly recognized as systemic disorders associated with chronic immune dysregulation. Growing evidence supports their links with metabolic disorders, reflected in heightened interest in therapeutic strategies targeting the immunometabolic axis. This review summarizes current knowledge on the role of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in the regulation of immune and metabolic processes in chronic inflammatory skin diseases, with particular emphasis on molecular mechanisms and available experimental and clinical data. GLP-1RAs, widely used in the treatment of type 2 diabetes and obesity, may also exhibit anti-inflammatory and immunomodulatory properties beyond their classical metabolic effects. GLP-1 signalling can influence keratinocyte function, immune cell activity, and wound healing. Furthermore, it modulates multiple intracellular signalling pathways, including cAMP/PKA, AMPK, PI3K/Akt, and NF-κB, as well as immune axes such as IL-23/Th17/IL-17 and inflammasome-related signalling. Available evidence suggests that GLP-1RAs may reduce inflammation and disease activity in selected inflammatory dermatoses. However, current evidence remains limited and is based primarily on experimental studies, case reports, and small-scale observational studies. Further well-designed clinical trials are needed to better define the therapeutic potential of GLP-1RAs and their role in dermatological practice.
SN  - 1999-4923
ER  -